VRDN Relative Valuation
VRDN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, VRDN is overvalued; if below, it's undervalued.
Historical Valuation
Viridian Therapeutics Inc (VRDN) is now in the Overvalued zone, suggesting that its current forward PS ratio of 8023.45 is considered Overvalued compared with the five-year average of -4.51. The fair price of Viridian Therapeutics Inc (VRDN) is between 9.64 to 14.56 according to relative valuation methord. Compared to the current price of 16.96 USD , Viridian Therapeutics Inc is Overvalued By 16.5%.
Relative Value
Fair Zone
9.64-14.56
Current Price：16.96
16.5%
Overvalued
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
3.19
P/B
Median3y
4.54
Median5y
3.93
-20.05
FCF Yield
Median3y
-15.62
Median5y
-21.66
Competitors Valuation Multiple
The average P/S ratio for VRDN's competitors is 1381.00, providing a benchmark for relative valuation. Viridian Therapeutics Inc Corp (VRDN) exhibits a P/S ratio of 8023.45, which is 480.99% above the industry average. Given its robust revenue growth of 0.00%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
FAQ
Is Viridian Therapeutics Inc (VRDN) currently overvalued or undervalued?
What is Viridian Therapeutics Inc (VRDN) fair value?
How does VRDN's valuation metrics compare to the industry average?
What is the current P/B ratio for Viridian Therapeutics Inc (VRDN) as of Jul 18 2025?
What is the current FCF Yield for Viridian Therapeutics Inc (VRDN) as of Jul 18 2025?
What is the current Forward P/E ratio for Viridian Therapeutics Inc (VRDN) as of Jul 18 2025?